三生国健股价涨5.25%，交银施罗德基金旗下1只基金重仓，持有158.43万股浮盈赚取457.86万元

Core Insights - Sangfor Technologies saw a 5.25% increase in stock price, reaching 57.99 CNY per share, with a trading volume of 444 million CNY and a turnover rate of 1.30%, resulting in a total market capitalization of 35.767 billion CNY [1] Company Overview - Sangfor Technologies was established on January 25, 2002, and went public on July 22, 2020. The company is located in the China (Shanghai) Free Trade Zone [1] - The main business activities of Sangfor Technologies include research, production, and sales of antibody drugs. The revenue composition is as follows: 75.24% from product sales, 15.37% from commissioned processing services, 7.94% from licensing services, and 1.44% from leasing services [1] Fund Holdings - According to data from the top ten holdings of funds, one fund under Jiao Yin Schroder has a significant position in Sangfor Technologies. The Jiao Yin Medical Innovation Stock A (004075) reduced its holdings by 786,100 shares, retaining 1,584,300 shares, which accounts for 3.31% of the fund's net value, ranking it as the tenth largest holding [2] - The Jiao Yin Medical Innovation Stock A (004075) was established on March 23, 2017, with a latest scale of 2.5 billion CNY. Year-to-date returns are 40.18%, ranking 359 out of 4222 in its category; over the past year, returns are 46.72%, ranking 1679 out of 3795; since inception, returns have reached 200.36% [2] - The fund manager, Lou Huiyuan, has been in the position for 6 years and 361 days, with total assets under management of 4.04 billion CNY. The best fund return during this period is 160.35%, while the worst is -21.93% [2]